Targacept, AZT Depression Drug Candidate Enters Home Stretch
Targacept Inc. and AstraZeneca have enrolled the first patient in a Phase III program for depression drug candidate TC-5214, which showed positive results in Phase II testing as an add-on therapy for patients who did not respond well to prior treatment with another antidepressant, citalopram. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.